Equities

Bioqual Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BIOQ:PKC

Bioqual Inc

Actions
  • Price (USD)37.51
  • Today's Change0.00 / 0.00%
  • Shares traded233.00
  • 1 Year change--
  • Beta-0.2343
Data delayed at least 15 minutes, as of Feb 06 2026 20:57 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BIOQUAL, Inc. provides contract research services primarily focused on animal models of human diseases including acquired immunodeficiency syndrome (AIDS), influenza, respiratory syncytial virus (RSV) infection, coronavirus infections (including COVID-19), flavivirus infections (including Zika and Dengue), malaria, hepatitis, cancer, and other infectious diseases. It also performs in vitro contract research services. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. Its services also encompass sample processing and custom assays for serology, cell-mediated immunity, viral loads, and bacterial enumeration. Its additional services include advanced biocontainment (BSL3), imaging services, animal model development, and IND-enabling services. Its lab services include cell-based assays, immunoassays, toxicity and cytotoxicity testing, viral load testing, and tailored assay development.

  • Revenue in USD (TTM)46.54m
  • Net income in USD453.25k
  • Incorporated1982
  • Employees108.00
  • Location
    Bioqual Inc9600 Medical Center Dr #101,ROCKVILLE 20850-3336United StatesUSA
  • Phone+1 (240) 404-7654
  • Fax+1 (240) 404-7664
  • Websitehttps://www.bioqual.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Palatin Technologies Inc8.85m-4.81m31.07m29.00--42.71--3.51-13.52-13.5212.390.40731.47----305,087.90-79.90-79.95---118.700.0091.70-54.32-1,326.05----0.00---100.00--41.80------
Tempest Therapeutics Inc0.00-36.05m31.14m24.00--1.65-----10.40-10.400.001.430.00----0.00-141.49-63.01-215.46-80.57------------0.00-------41.88--1.85--
Werewolf Therapeutics Inc0.00-72.84m31.73m39.00--1.04-----1.62-1.620.000.62640.00----0.00-66.32-33.10-76.84-36.81-------593.05---54.290.4829---90.55---88.70---0.919--
Jasper Therapeutics Inc0.00-91.02m31.90m64.00--2.76-----5.90-5.900.000.41350.00----0.00-116.04-75.11-147.54-86.11------------0.00-------10.55------
Atara Biotherapeutics Inc151.93m23.40m32.09m38.002.03--1.210.21122.192.1912.81-5.081.763.9993.55993,006.6027.07-67.79---93.0781.63--15.40-558.471.0215.248.31--1,404.02--69.07---46.73--
Onkure Therapeutics Inc0.00-81.21m32.79m46.00--0.4936-----12.78-12.780.004.900.00----0.00-107.93-48.73-115.20-53.34------------0.00------31.94--49.34--
Promis Neurosciences Inc0.00-29.28m32.82m6.00--3.57-----18.62-18.620.004.270.00-------127.41-85.65-188.18-145.08-------3,184,250.00----0.00------121.03------
Bioqual Inc46.54m453.25k33.55m108.0074.020.93812.220.72090.50680.506852.0339.990.7111--3.19--0.69264.120.77454.8312.8516.150.9744.03----0.0032.81-16.601.06-316.79---36.99-6.51
Cell Source Inc0.00-6.57m34.03m-----------0.1613-0.16130.00-0.43790.00-------2,039.39-1,758.85---------------3.74---------3.55------
Actinium Pharmaceuticals Inc90.00k-34.60m34.63m37.00--2.51--384.75-1.11-1.110.00290.44190.0013----2,432.43-50.05-43.20-55.95-47.84-----38,443.33-7,408.74----0.0009---100.00--21.66---29.66--
Neurosense Therapeutics Ltd0.00-8.66m34.73m15.00---------0.361-0.3610.00-0.02110.00----0.00-491.23-145.64---198.79---------------------1.02---15.59--
Tvardi Therapeutics Inc4.02m-13.95m34.90m10.00--1.25--8.67-8.36-8.360.77092.970.0891----402,400.00-30.87-36.79-40.26-41.45100.00---346.55-155.60----0.00---65.96-18.5340.20--125.35--
NextCure Inc0.00-58.01m35.11m43.00--1.48-----24.19-24.190.008.840.00----0.00-89.28-27.70-105.20-28.91-------1,336.59----0.00------11.27---32.45--
Outlook Therapeutics Inc1.51m-62.42m36.02m17.00------23.93-1.61-1.610.0432-0.59730.0635----88,548.23-263.36-240.08----70.78---4,146.95-22,354.500.3067-200.54--------17.17------
Atossa Therapeutics Inc0.00-30.18m36.17m13.00--0.7265-----3.52-3.520.005.780.00----0.00-43.90-26.93-48.89-29.04------------0.00------15.25--20.02--
Data as of Feb 06 2026. Currency figures normalised to Bioqual Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.